An Ottawa tech firm is putting its unique DNA testing capabilities towards detecting early indicators of Alzheimer’s disease.
Spartan Bioscience announced Wednesday a partnership with the Global Alzheimer’s Platform Foundation to help recruit for clinical trials targeting the chronic neurodegenerative disease.
Spartan, known for its distinctive DNA testing cube, has developed a genetic pre-screening test capable of detecting whether subjects carry a particular gene variation that puts them at higher risk of developing Alzheimer’s. According to a release, these individuals might be “ideal clinical trial candidates” for research on the disease.
(Sponsored)
How The Ottawa Hospital uses AI tools to boost health outcomes and streamline clinical efficiency
Dr. Douglas Manuel says it all began with the Ottawa Ankle Rules algorithm, a set of clinical guidelines developed in the early 1990s by The Ottawa Hospital’s Dr. Ian Stiell
Ottawa businesses critically important to ending youth homelessness across the city
Local businesses joining United Way East Ontario’s effort to prevent and end youth homelessness not only helps build a stronger, safer, and healthier community, but gives a boost to Ottawa’s
Through the announced partnership, Spartan will also contribute $5 from each sale of its pre-screening test towards GAP’s transportation program, which providers Alzheimer’s clinical trial participants with rides to and from their appointments.
Spartan notes that its test is currently cleared for research uses only, not diagnosis.
